

Crefmirlimab

Chemical Properties

CAS No. : 2611099-93-3

Formula:

Molecular Weight:

Storage: Store at low temperature
Store at -20°C

Actual storage temperature shall be subject to the COA.

Biological Description

Description	Crefmirlimab (IAB22M2C) is a humanized anti-CD8 monoclonal antibody fragment (minibody) designed for PET imaging. Upon radiolabeling (e.g., with ⁸⁹ Zr), it serves as a non-invasive imaging biomarker that binds with high affinity and specificity to the CD8 receptor on CD8+ T cells, enabling real-time, dynamic tracking of T-cell distribution, infiltration, and trafficking in vivo in both preclinical models and clinical studies. It is a critical tool for evaluating the pharmacodynamics of T-cell engaging therapies (such as the GUCY2C-CD3 bispecific antibody PF-07062119) and for investigating the tumor immune microenvironment
Targets(IC50)	Immunology/Inflammation related
In vitro	In cell-binding assays, Crefmirlimab (IAB22M2C) demonstrates high specificity and binding affinity for CD8 receptors expressed on human T cells, enabling sensitive detection and quantification of CD8+ populations without inducing significant T-cell activation or effector functions [1].
In vivo	In tumor-bearing mice, IV injection of radiolabeled Crefmirlimab (⁸⁹ Zr-Df-IAB22M2C) enables PET imaging to track the dynamic infiltration of CD8+ T cells into tumors and lymphoid organs. The study confirms its utility as a non-invasive biomarker for assessing therapeutic response and immune activation [1].

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481